Drivers of medicine spending in a public hospital in Rio de Janeiro Brazil from 2013 to 2020
DOI:
https://doi.org/10.33448/rsd-v11i15.33885Keywords:
Drug costs; Pharmaceuticals Services; Hospitals.Abstract
Medicines are important drives of health expenditure. To ensure that all patients have access to this technology is challenging given the financial constraints of health systems. The aim of this study was to analyze drug expenditures and their drivers in a public hospital located in Rio de Janeiro, Brazil, from 2013 to 2020. All data regarding drug purchases were retrieved from the database of the hospital Information System used to manage health products purchases. The pharmaceutical products were classified in accordance with the Anatomical, Therapeutic, and Chemical (ATC) classification system coordinated by the WHO Collaborating Centre for Drug Statistics Methodology and aggregated by volume and by expenditure. The expenditure variation was decomposed into three broad categories: price effects, quantity effects, and drug mix effects. During the period, annual expenditure reduced by 20%, ranging from from R$ 16.9 million in 2013 to R$ 13.4 million in 2020, while purchased quantities also dropped by 33.7%, ranging from 5.7 million in 2013 to 3.8 million unites in 2020. Two factors drove the reducition of expenditures, the quantity effect and the price effect. These findings may contribute to better understanding medicine spending trends and the factors that influence them in order to formulate strategies to optimize resource utilization and improve patients access to the necessary tratments.
References
Addis, A., & Magrini, N. (2002). New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence‐based reports to prescribers. Pharmacoepidemiology and drug safety, 11(8), 721-726.
Alves, J. D. C., Osorio-de-Castro, C. G. S., Wettermark, B., & Luz, T. C. B. (2018). Immunosuppressants in Brazil: underlying drivers of spending trends, 2010–2015. Expert Review of Pharmacoeconomics & Outcomes Research, 18(5), 565-572.
Resolução nº 466, de 12 de dezembro de 2012 (2012). Dispõe sobre as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. https://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf.
Resolução nº 510, de 07 de abril de 2016 (2016). Dispõe sobre as normas aplicáveis a pesquisas em Ciências Humanas e Sociais cujos procedimentos metodológicos envolvam a utilização de dados diretamente obtidos com os participantes ou de informações identificáveis ou que possam acarretar riscos maiores do que os existentes na vida cotidiana, na forma definida nesta Resolução. http://conselho.saude.gov.br/resolucoes/2016/Reso510.pdf.
Belloni, A., Morgan, D., & Paris, V. (2016). Pharmaceutical expenditure and policies: past trends and future challenges. OECD Health Working Papers, (87).
Bermudez, J. A. Z., Oliveira, M. A., & Chaves, G. C. (2016). Novos medicamentos: quem poderá pagar? Cadernos de Saúde Pública, 32, e00025215.
Caetano, R. (2014). Avaliação de Tecnologias em Saúde. In: Osorio de castro, C. G. S., Luiza, V. L., Castilho, S. R., Oliveira, M. A., & Jaramillo, N. M. (Orgs.). Assistência Farmacêutica – Gestão e Prática para Profissionais da Saúde (cap. 15). Rio de janeiro: Fiocruz.
Carpanez, L. R., & Malik, A. M. (2021). O efeito da municipalização no sistema hospitalar brasileiro: os hospitais de pequeno porte. Ciência & Saúde Coletiva, 26, 1289-1298.
Chay, J., Donovan, P., Cummins, L., Kubler, P., & Pillans, P. (2013). Experience with low‐dose rituximab in off‐label indications at two tertiary hospitals. Internal Medicine Journal, 43(8), 871-882.
Danes, I., Agustí, A., Vallano, A., Martínez, J., Alerany, C., Ferrer, A., Lopez, A, Cortes Hernadez, J., & Bosch, J. A. (2013). Available evidence and outcome of off-label use of rituximab in clinical practice. European journal of clinical pharmacology, 69(9), 1689-1699.
DATASUS (2022) Tecnologia da Informação a Serviço do SUS. 2022. http://tabnet.datasus.gov.br/cgi/deftohtm.exe?cnes/cnv/leiintbr.def.
David, G., Andrelino, A., & Beghin, N. (2016). Direito a Medicamentos. Avaliação das Despesas com Medicamentos no Âmbito Federal do Sistema Único de Saúde entre 2008 e 2015. Brasília: Inesc.
Gadelha, C. A. G., & Temporão, J. G. (2018). Desenvolvimento, Inovação e Saúde: a perspectiva teórica e política do Complexo Econômico-Industrial da Saúde. Ciência e Saúde Coletiva, 23, 1891-1902.
Gallego, G., Melocco, T., Taylor, S. J., & Brien, J. A. E. (2004). Impact of High‐Cost Drugs for Individual Patient Use. Journal of Pharmacy Practice and Research, 34(2), 100-103.
Gerdtham, U. G., Johannesson, M., Gunnarsson, B., Marcusson, M., & Henriksson, F. (1998). The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics, 13(1), 127-134.
Gomes, M. J. V. M., Reis, A. M. M. & Rosa, M.B. (2003). Abastecimento e gerenciamento de materiais. In: Magalhães, M. J. V.; Reis, A. M. M. (Orgs.) Ciências farmacêuticas: uma abordagem em farmácia hospitalar. São Paulo: Atheneu.
Hensher, M., Tisdell, J., & Zimitat, C. (2017). “Too much medicine”: Insights and explanations from economic theory and research. Social science & medicine, 176, 77-84.
IMS Institute for Healthcare Informatics (2016). Delivering on the potencial of biosimilar medicines – The role of Functioning competitive markets. IMS Institute for Healthcare Informatics, 2016. https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf.
IBGE, Instituto Brasileiro de Geografia e Estatística (2022). Variação acumulada no ano durante o Plano Real (%), dezembro 1995 - dezembro 2021. https://www.ibge.gov.br/estatisticas/economicas/precos-e-custos/9256-indice-nacional-de-precosconsumidor-amplo.html?edicao=20932&t=series-historicas.
Inglis, J. M., Caughey, G. E., & Shakib, S. (2019). Use of non-formulary high-cost medicines in an Australian public hospital. International Journal of Clinical Pharmacy, 41(4), 920-931.
Light, D. W., & Kantarjian, H. (2013). Market spiral pricing of cancer drugs. Cancer, 119(22), 3900-3902.
Kar, S. S., Pradhan, H. S., & Mohanta, G. P. (2010). Concept of essential medicines and rational use in public health. Indian journal of community medicine: official publication of Indian Association of Preventive & Social Medicine, 35(1), 10.
Karikios, D. J., Schofield, D., Salkeld, G., Mann. K., P., Trotman, J., & Stockler, M. R. (2014). Rising Cost of Anticancer Drugs in Australia. Internal Medical Journal, 44(5), 458-463.
Karampli, E., Souliotis, K., Polyzos, N., Kyriopoulos, J., & Chatzaki, E. (2014). Pharmaceutical innovation: impact on expenditure and outcomes and subsequent challenges for pharmaceutical policy, with a special reference to Greece. Hippokratia, 18(2), 100.
Kastanioti, C., Mavridoglou, G., Karanikas, H., & Polyzos, N. (2016). ABC analysis: a tool of effectively controlling pharmaceutical expenditure in Greek NHS hospitals. Journal of Pharmaceutical Health Services Research, 7(3), 173-179.
Kivoto, P. M., Mulaku, M., Ouma, C., Ferrario, A., Kurdi, A., Godman, B., & Oluka, M. (2018). Clinical and financial implications of medicine consumption patterns at a leading referral hospital in Kenya to guide future planning of care. Frontiers in pharmacology, 9, 1348.
Kwon, H. Y., Yang, B., & Godman, B. (2015). Key components of increased drug expenditure in South Korea: implications for the future. Value in Health Regional Issues, 6, 14-21.
La Forgia, G. M., & Couttolenc, B. F (2009). Desempenho hospitalar no Brasil: a busca da excelencia. The World Bank.
Lima, E. D. C., Sandes, V. D. S., Caetano, R., & Osorio-de-Castro, C. G. S. (2010). Incorporação e gasto com medicamentos de relevância financeira em hospital universitário de alta complexidade. Caderno saúde coletiva, 18(4), 551-559.
Luchese, M. D., Bertolini, S. R., Moro, A. M., & Larentis, A. L. (2017). Dependência tecnológica na produção de imunobiológicos no Brasil: transferência de tecnologia versus pesquisa nacional. Univ Soc, 59, 46-54.
Luz, T. C. B., Garcia Serpa Osorio-de-Castro, C., Magarinos-Torres, R., & Wettermark, B. (2017). Trends in medicines procurement by the Brazilian federal government from 2006 to 2013. Policy Impact Collection, 12(4).
Machado, C. V., Lima, L. D. D., & Andrade, C. L. T. D. (2014). Federal funding of health policy in Brazil: trends and challenges. Cadernos de Saúde Pública, 30, 187-200.
Mendes, A, Funcia, F. R. & Marques, R. M (2016). O SUS e seu financiamento. In: Marques, R.; Piola, S. F.; Roa, A. C. (Org.). Sistema de Saúde no Brasil: organização e financiamento (p. 139-168). Rio de Janeiro: Abres, MS, OPAS/OMS.
Novaes, M. R. C. G., Souza, N. N. R., Néri, E. D. R., Carvalho, F., Bernardino, H., & Marcos, J. (2009). Guia de boas práticas em Farmácia Hospitalar e Serviços de Saúde-SBRAFH. São Paulo: Ateliê Vide o Verso.
OECD (2015). Health at a Glance 2015: OECD Indicators. Paris: OECD Publishing. https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2015_health_glance-2015-en.
Prosser, H., & Walley, T. (2006). New drug prescribing by hospital doctors: the nature and meaning of knowledge. Social Science & Medicine, 62(7), 1565-1578.
Rye, C. B., & Kimberly, J. R. (2007). The adoption of innovations by provider organizations in health care. Medical Care Research and Review, 64(3), 235-278.
Serra-Sastre, V., & Mcguire, A. (2009). Diffusion of health Technologies: evidence from the pharmaceutical sector. In: Joan, C. F., Courbage, C. & Mcguire, A (Eds.). The Economics of New Technologies: incentives, organization and financing (p. 53-74, 2009). England: Oxford University press.
Silva, L. P. A. (2020). Orçamento temático de acesso a medicamentos 2019. Brasília: Inesc.
Souza, K. A. D. O., & Souza, L. E. P. F. D. (2018). Incorporação de tecnologias no Sistema Único de Saúde: as racionalidades do processo de decisão da Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde. Saúde em Debate, 42, 48-60.
Statista (2016, Jun 20). Oncology spending as a percentage of total pharmaceutical spending in selected countries in 2015. 2021. https://www.statista.com/statistics/696055/oncology-spending-as-share-of-pharma-spending-by-country/.
Tordoff, J. M., Norris, P. T., & Reith, D. M. (2008). “Price management” and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals. Value in Health, 11(7), 1214-1226.
Trindade, E. (2008). A incorporação de novas tecnologias nos serviços de saúde: o desafio da análise dos fatores em jogo. Cadernos de saúde pública, 24, 951-964.
Vidal, T. J., Figueiredo, T. A., & Pepe, V. L. E. (2018). O mercado brasileiro de anticorpos monoclonais utilizados para o tratamento de câncer. Cadernos de Saúde Pública, 34.
Vieira, F. S. (2018). Evolução do gasto com medicamentos do Sistema Único de Saúde no período de 2010 a 2016 (N0 2356). Texto para Discussão.
Wannmacher, L. (2006). Quanto é evidente a evidência na saúde. Uso Racional de Medicamentos–Temas selecionados. Brasília, 3(5).
World Health Organization (WHO). (2010). Relatório Mundial da Saúde. Financiamento dos Sistemas de Saúde. Publicações da OMS. https://www.who.int/eportuguese/publications/pt/.
World Health Organization (WHO). (2003). Introduction to Drug Utilization Research/WHO International Working Group for Drug Statistics Methodology. WHO Collaborating Center for Drug Statistics Methodology. World Health Organization, Oslo, Norway.
World Health Organization (WHO). (2021). Collaborating Centre for Drug Statistics Methodology (WHOCC). Guidelines for ATC Classification and DDD assignment 2022. Oslo: WHO. https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Maria Aparecida Corrêa da Silva; Milene Rangel da Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
